NCT06906471 A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
| NCT ID | NCT06906471 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Antelope Surgical Solutions, Inc |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2026-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2026-07-01 with a primary completion date of 2026-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS
Eligibility Criteria
Inclusion Criteria: * suspected prostate cancer warranting standard of care multi-core prostate biopsy Exclusion Criteria: * Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment * Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature * Patients with a creatinine clearance cutoff (CrCl) of \< 60 mL/min
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06906471 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 90 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06906471 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06906471 currently recruiting?
Yes, NCT06906471 is actively recruiting participants. Contact the research team at info@antelopesurgical.com for enrollment information.
Where is the NCT06906471 trial being conducted?
This trial is being conducted at Miami, United States, New York, United States.
Who is sponsoring the NCT06906471 clinical trial?
NCT06906471 is sponsored by Antelope Surgical Solutions, Inc. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.